Department of Medicine, Weill Cornell Medicine/New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, USA
Volume 28, Issue 3, September 2017
Sign in to download the Issue in PDF format.
149343459
Mediterr J Rheumatol 2017;28(3):153-6
Article Links
Oxygen-dependent patient with antisynthetase syndrome associated interstitial lung disease responds promptly to rituximab with rapid pulmonary function improvement
References
- Oddis C V, Conte C G, Steen V D, Medsger T A Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990;17:1329-34.
- Solomon J, Swigris J J, Brown K K. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 2011;37:100-9.
- Stone K B, Oddis C V, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007;56:3125-31.
- Chatterjee S, Paryson R, Farver C. Antisynthetase syndrome: Not just an inflammatory myopathy. Cleve Clin J Med 2013;80:655-66.
- Malhotra G, Ramreddy N, Chua S, Iliescu M, Kaur T. A Curious Case of Acute Respiratory Failure: Is It Antisynthetase Syndrome? Case Rep Crit Care 2016;2016:7379829.
- Dasa O, Ruzieh M, Oraibi O. Successful Treatment of Life-Threatening Interstitial Lung Disease Secondary to Antisynthetase Syndrome Using Rituximab: A Case Report and Review of the Literature. Am J Ther 2016 Mar-Apr;23:e639-45.
- Lepri G, Avouac J, Airo P, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol 2016;34:S181-S185.
- Shinjo S K, Levy-Neto M. Anti-Jo-1 antisynthetase syndrome. Rev Bras Rheumatol 2010;50:492-500.
- Sem M, Molberg O, Lund MB, Gran J T. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009;48:968-71.
- Allenbach Y, Guiguet M, Rigolet A, et al. Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. Maher T M, ed. PLoS ONE 2015;10:e0133702.